Hiront Tablet 60mg (Ticagrelor)

Adult dose

This drug should not be used concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180 mg, followed by 90 mg twice daily. Treatment is recommended for 12 months unless discontinuation is clinically necessary. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. In patients with acute coronary syndrome who have an increased risk of bleeding and have undergone percutaneous coronary intervention (PCI), monotherapy with this drug (discontinuation of aspirin) may be considered after 3 months of concomitant treatment with this drug and aspirin. (See 3. Patients Requiring Caution in Administration.) Patients with a history of myocardial infarction (occurring at least 1 year previously) and at high risk of thrombotic cardiovascular events: Administer 60 mg twice daily. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - Patients who took this drug 90 mg or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with this drug at 60 mg. - Treatment with this drug may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). - The safety and efficacy of this drug were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60 mg twice daily. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - Refer to the dosage and administration for patients with acute coronary syndrome. - Data on the safety and efficacy of this drug for treatment exceeding 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180 mg, followed by 90 mg twice daily for 30 days. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. This drug is administered orally and may be taken with or without food. Patients who have difficulty swallowing tablets should crush this drug into a fine powder, disperse it in half a glass of water, and drink the mixture immediately, then rinse the glass used with half a glass of water and drink it again. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the tube with water after administration. When switching from another antiplatelet agent to this drug, start this drug 24 hours after the last dose of the previous medication. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This drug has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Child dose

The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age (see “Other” section).

This medication prevents platelets in the blood from sticking together, which helps prevent thrombosis. However, it may increase the risk of bleeding if the blood becomes too thin, so it should not be used in patients with active bleeding or a history of intracranial hemorrhage. It should be discontinued at least 5 days before any surgery to reduce the risk of bleeding. If bleeding symptoms appear, the patient must inform a doctor immediately, and if possible, treatment for bleeding should be administered without discontinuing the medication. Patients with an allergy to any component of this medication, those with severe liver impairment, or those taking strong CYP3A4 inhibitors should not take this medication. Patients at high risk of bleeding, those who have recently undergone surgery, those with bradycardia (slow heart rate), or those with dyspnea should use this medication cautiously. Specifically, patients with asthma or chronic obstructive pulmonary disease (COPD) should be careful as dyspnea may worsen. This medication may also affect blood test results, so it's essential to inform the doctor about its use when undergoing platelet-related testing. This medication can interact with several other drugs, so patients must inform their physician or pharmacist about any other medications they are taking. Pregnant or breastfeeding women must consult an expert before using this medication, and it is not recommended for children under 18 years old. Overdose may increase the risk of bleeding, and since there is no specific antidote, patients should visit a medical facility for appropriate treatment immediately. This medication can cause dizziness and confusion, so caution is advised when driving or operating machinery while taking it. Patients should regularly monitor kidney function and bleeding symptoms during treatment and consult healthcare professionals if any abnormal symptoms appear.

Bleeding, dyspnea, hyperuricemia, gout, confusion, dizziness, syncope, headache, intracranial hemorrhage, ocular hemorrhage, vertigo, ear bleeding, hypotension, respiratory tract bleeding, gastrointestinal bleeding, diarrhea, nausea, dyspepsia, constipation, retroperitoneal hemorrhage, subcutaneous or cutaneous bleeding, rash, pruritus, muscle bleeding, urinary tract bleeding, genital bleeding, elevated serum creatinine, post-procedural bleeding, traumatic bleeding, thrombotic thrombocytopenic purpura, bradyarrhythmia, atrioventricular block, angioedema, central sleep apnea including Cheyne-Stokes respiration, chest pain, pulmonary hemorrhage, pharyngitis, upper respiratory infection, asthma, pleural effusion, bronchitis, pneumothorax, pneumonia, pulmonary edema, weakness, anaphylactic shock, epistaxis, hemoptysis, hematoma, cerebrovascular hemorrhage, spinal stenosis, dementia, migraine, paralysis, gait disturbance, rectal bleeding, anal bleeding, appendicitis, tendonitis, bursitis, rhabdomyolysis, hepatitis, snoring, aneurysm, heart failure, cardiac arrhythmia, palpitations, ventricular tachycardia, arrhythmia, ventricular fibrillation, cardiac arrest, ventricular fibrillation, urinary tract infection, kidney stones, arterial stenosis, angina pectoris, coronary thrombosis, myocardial ischemia, palpitations, bradycardia, atrial fibrillation, atrial fibrillation, ventricular tachycardia, cardiac arrest, ventricular fibrillation, complete heart block, anemia, vestibular disorders, malignant neoplasm of the male reproductive system, chemical poisoning, post-procedural hematoma, laceration, road traffic accident, trauma, nausea, vomiting, acute renal failure, cerebral infarction, myocardial infarction, edema, fatigue, pain, insomnia, anxiety, memory impairment, erectile dysfunction, agitation, orthostatic hypotension, exacerbation of hypertension, hypertension, palpitations, pollakiuria, dysuria, urinary tract infection, ocular congestion, eye pain, visual disturbances, decreased blood iron, tinnitus, ear pain, lymphadenopathy, eosinophilia, sexual dysfunction, benign prostatic hyperplasia, ovarian cyst, amenorrhea, vaginitis, injection site reaction, injection site pain, increased sweating, urticaria, contact dermatitis, fungal dermatitis, skin disease, erythematous rash, hyperkeratosis, acute urticaria, onychomycosis, hair loss, scleroderma, dermatofibroma, taste loss, abnormal olfaction, increased TSH, hypothyroidism

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is best to store it at room temperature between 1 degree and 30 degrees.

Appearance

Pink, round, convex film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)